HanAll\'s Partner HBM Completes First Dosing of Phase 2 of Batoclimab in TED in China
2021.10.20

 

HanAll Biopharma(KRX: 009420.KS) announced that its partner Harbour BioMed had completed the first dosing of the first patient in Phase 2 of batoclimab in thyroid eye disease(TED) ​ in China. ​

 

For more information, please refer to the link below.

- HBM\'s press release link: https://www.harbourbiomed.com/news/168.html